Clinical Trial Update: Rivet PVS Therapy in Group 2 PH-HFpEF [NA]

View source ↗

Summary

The trial investigating Rivet PVS Therapy for Group 2 pulmonary hypertension with heart failure with preserved ejection fraction has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Pulmonary Hypertension

Drugs mentioned

• Rivet PVS Therapy

Snippet

Sponsor: NXT Biomedical | Conditions: Heart Failure, Pulmonary Hypertension | NA | Status: WITHDRAWN